Acetylcholinesterase inhibitors and cholinergic modulation in Myasthenia Gravis and neuroinflammation

Journal of Neuroimmunology

Volumn 201-202, Issue C, 2008, Pages 121-127

  Brenner, Talma ^a   Nizri, Eran ^a   Irony Tur Sinai, Michal ^a   Hamra Amitay, Yasmine ^a   Wirguin, Itzhak ^b  

^a Agnes Ginges Center for Human Neurogenetics   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

7 Acetylcholine receptor; Acetylcholinesterase inhibitors; Alzheimer's disease; Inflammation; Multiple Sclerosis; Myasthenia Gravis

Indexed keywords

ALPHA BUNGAROTOXIN; ANTISENSE OLIGODEOXYNUCLEOTIDE; BETA SECRETASE; CHOLINERGIC RECEPTOR; CHOLINESTERASE INHIBITOR; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYTISINE; DONEPEZIL; EN 101; IBUPROFEN; MUSCARINIC M1 RECEPTOR AGONIST; PYRIDOSTIGMINE; RIVASTIGMINE; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CELL PROLIFERATION; CHOLINERGIC TRANSMISSION; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG PENETRATION; EATON LAMBERT SYNDROME; ELECTRODIAGNOSIS; ELECTROMYOGRAPHY; EXTRAOCULAR MUSCLE; HUMAN; IMMUNOCOMPETENT CELL; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NERVE STIMULATION; NEUROMUSCULAR SYNAPSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RANGE OF MOTION; T LYMPHOCYTE; TREATMENT DURATION;

ACETYLCHOLINE; ALZHEIMER DISEASE; ANIMALS; CHOLINESTERASE INHIBITORS; HUMANS; INFLAMMATION; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS;

EID: 51849146029     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.05.022     Document Type: Article

References (58)

1. Guidelines in electrodiagnostic medicine. American Association of Electrodiagnostic Medicine. Muscle Nerve 15 (1992) 229-253
2. Aisen P.S., Davis K.L., Berg J.D., Schafer K., Campbell K., Thomas R.G., Weiner M.F., Farlow M.R., Sano M., Grundman M., and Thal L.J. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 54 (2000) 588-593
3. Aisen P.S., Schafer K.A., Grundman M., Pfeiffer E., Sano M., Davis K.L., Farlow M.R., Jin S., Thomas R.G., and Thal L.J. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. Jama 289 (2003) 2819-2826
4. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., and Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 21 (2000) 383-421
5. Amato M.P., Portaccio E., and Zipoli V. Are there protective treatments for cognitive decline in MS?. J. Neurol. Sci. 245 (2006) 183-186
6. Argov Z., and Wirguin I. Drugs and the neuromuscular junction: pharmacotherapy and adverse effects in transmission disorders. In: Lisak R. (Ed). Handbook of myasthenia gravis (1994), Marcel-Dekker, New-York 295-319
7. Argov Z., McKee D., Agus S., Brawer S., Shlomowitz N., Yoseph O.B., Soreq H., and Sussman J.D. Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase. Neurology 69 (2007) 699-700
8. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., and Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6 (2000) 916-919
9. Barnes P.J., and Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336 (1997) 1066-1071
10. Bjartmar C., Wujek J.R., and Trapp B.D. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J. Neurol. Sci. 206 (2003) 165-171
11. Boneva N., Hamra-Amitay Y., Wirguin I., and Brenner T. Stimulated-single fiber electromyography monitoring of anti-sense induced changes in experimental autoimmune myasthenia gravis. Neurosci. Res. 55 (2006) 40-44
12. Borovikova L.V., Ivanova S., Zhang M., Yang H., Botchkina G.I., Watkins L.R., Wang H., Abumrad N., Eaton J.W., and Tracey K.J. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405 (2000) 458-462
13. Brenner T., Hamra-Amitay Y., Evron T., Boneva N., Seidman S., and Soreq H. The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis. FASEB J. 17 (2003) 214-222
14. Christodoulou C., MacAllister W.S., McLinskey N.A., and Krupp L.B. Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option?. CNS Drugs 22 (2008) 87-97
15. Conti-Fine B.M., Milani M., and Kaminski H.J. Myasthenia gravis: past, present, and future. J Clin. Investig. 116 (2006) 2843-2854
16. Cummings J.L. Alzheimer's disease. N. Engl. J. Med. 351 (2004) 56-67
17. D'Intino G., Paradisi M., Fernandez M., Giuliani A., Aloe L., Giardino L., and Calza L. Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 3070-3075
18. De Simone R., Ajmone-Cat M.A., Carnevale D., and Minghetti L. Activation of alpha7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. J. Neuroinflammation 2 (2005) 4
19. Desai A.K., and Grossberg G.T. Diagnosis and treatment of Alzheimer's disease. Neurology 64 (2005) S34-S39
20. Drachman D.B. Myasthenia gravis. N. Engl. J. Med. 330 (1994) 1797-1810
21. Fujii T., and Kawashima K. YM905, a novel M3 antagonist, inhibits Ca2+ signaling and c-fos gene expression mediated via muscarinic receptors in human T cells. Gen. Pharmacol. 35 (2000) 71-75
22. Giacobini E. Cholinesterases: new roles in brain function and in Alzheimer's disease. Neurochem. Res. 28 (2003) 515-522
23. Grisaru D., Sternfeld M., Eldor A., Glick D., and Soreq H. Structural roles of acetylcholinesterase variants in biology and pathology. Eur. J. Biochem. 264 (1999) 672-686
24. Hemmer B., Archelos J.J., and Hartung H.P. New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev., Neurosci. 3 (2002) 291-301
25. Hock C., Maddalena A., Raschig A., Muller-Spahn F., Eschweiler G., Hager K., Heuser I., Hampel H., Muller-Thomsen T., Oertel W., Wienrich M., Signorell A., Gonzalez-Agosti C., and Nitsch R.M. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid 10 (2003) 1-6
26. Inestrosa N.C., Alvarez A., Godoy J., Reyes A., and De Ferrari G.V. Acetylcholinesterase-amyloid-beta-peptide interaction and Wnt signaling involvement in Abeta neurotoxicity. Acta Neurol. Scand., Suppl. 176 (2000) 53-59
27. Inestrosa N.C., Alvarez A., Dinamarca M.C., Perez-Acle T., and Colombres M. Acetylcholinesterase-amyloid-beta-peptide interaction: effect of Congo Red and the role of the Wnt pathway. Curr. Alzheimer Res. 2 (2005) 301-306
28. Kaduszkiewicz H., Zimmermann T., Beck-Bornholdt H.P., and van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 331 (2005) 321-327
29. Kaminski H.J. Restoring balance at the neuromuscular junction. Neurology 69 (2007) 629-630
30. Kawashima K., and Fujii T. The lymphocytic cholinergic system and its biological function. Life Sci. 72 (2003) 2101-2109
31. Kesselring J., and Beer S. Symptomatic therapy and neurorehabilitation in multiple sclerosis. Lancet Neurol. 4 (2005) 643-652
32. Krupp L.B., Christodoulou C., Melville P., Scherl W.F., MacAllister W.S., and Elkins L.E. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 63 (2004) 1579-1585
33. Monsonego A., and Weiner H.L. Immunotherapeutic approaches to Alzheimer's disease. Science 302 (2003) 834-838
34. Monsonego A., Zota V., Karni A., Krieger J.I., Bar-Or A., Bitan G., Budson A.E., Sperling R., Selkoe D.J., and Weiner H.L. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J. Clin. Invest. 112 (2003) 415-422
35. Murray T.J. Diagnosis and treatment of multiple sclerosis. BMJ 332 (2006) 525-527
36. Newsom-Davis J. Lambert-Eaton myasthenic syndrome. Rev. Neurol. (Paris) 160 (2004) 177-180
37. Newsom-Davis J. The emerging diversity of neuromuscular junction disorders. Acta Myol. 26 (2007) 5-10
38. Nitsch R.M., Slack B.E., Wurtman R.J., and Growdon J.H. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258 (1992) 304-307
39. Nizri E., Adani R., Meshulam H., Amitai G., and Brenner T. Bifunctional compounds eliciting both anti-inflammatory and cholinergic activity as potential drugs for neuroinflammatory impairments. Neurosci. Lett. 376 (2005) 46-50
40. Nizri E., Hamra-Amitay Y., Sicsic C., Lavon I., and Brenner T. Anti-inflammatory properties of cholinergic up-regulation: a new role for acetylcholinesterase inhibitors. Neuropharmacology 50 (2006) 540-547
41. Nizri E., Irony-Tur-Sinai M., Grigoriadis N., Abramsky O., Amitai G., and Brenner T. Novel approaches to treatment of autoimmune neuroinflammation and lessons for drug development. Pharmacology 79 (2007) 42-49
42. Nizri E., Irony-Tur-Sinai M., Lavon I., Meshulam H., Amitai G., and Brenner T. IBU-octyl-cytisine, a novel bifunctional compound eliciting anti-inflammatory and cholinergic activity, ameliorates CNS inflammation by inhibition of T-cell activity. Int. Immunopharmacol. 7 (2007) 1129-1139
43. Pollak Y., Gilboa A., Ben-Menachem O., Ben-Hur T., Soreq H., and Yirmiya R. Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production. Ann. Neurol. 57 (2005) 741-745
44. Punga A.R., Sawada M., and Stalberg E.V. Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis. Muscle Nerve 37 (2008) 300-307
45. Razani-Boroujerdi S., Behl M., Hahn F.F., Pena-Philippides J.C., Hutt J., and Sopori M.L. Role of muscarinic receptors in the regulation of immune and inflammatory responses. J. Neuroimmunol. 194 (2008) 83-88
46. Reale M., Iarlori C., Gambi F., Feliciani C., Salone A., Toma L., DeLuca G., Salvatore M., Conti P., and Gambi D. Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. J. Neuroimmunol. 148 (2004) 162-171
47. Reale M., Iarlori C., Gambi F., Feliciani C., Isabella L., and Gambi D. The acetylcholinesterase inhibitor, Donepezil, regulates a Th2 bias in Alzheimer's disease patients. Neuropharmacology 50 (2006) 606-613
48. Scharf S., Mander A., Ugoni A., Vajda F., and Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 53 (1999) 197-201
49. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., and Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
50. Shytle R.D., Mori T., Townsend K., Vendrame M., Sun N., Zeng J., Ehrhart J., Silver A.A., Sanberg P.R., and Tan J. Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J. Neurochem. 89 (2004) 337-343
51. Steinman L. Multiple sclerosis: a two-stage disease. Nat. Immunol. 2 (2001) 762-764
52. Steinman L., and Zamvil S.S. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 60 (2006) 12-21
53. Stip E., Sepehry A.A., and Chouinard S. Add-on therapy with acetylcholinesterase inhibitors for memory dysfunction in schizophrenia: a systematic quantitative review, part 2. Clin. Neuropharmacol. 30 (2007) 218-229
54. Tabet N. Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing!. Age Ageing 35 (2006) 336-338
55. Teaktong T., Graham A., Court J., Perry R., Jaros E., Johnson M., Hall R., and Perry E. Alzheimer's disease is associated with a selective increase in alpha7 nicotinic acetylcholine receptor immunoreactivity in astrocytes. Glia 41 (2003) 207-211
56. Wang H., Yu M., Ochani M., Amella C.A., Tanovic M., Susarla S., Li J.H., Yang H., Ulloa L., Al-Abed Y., Czura C.J., and Tracey K.J. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421 (2003) 384-388
57. Wyss-Coray T., and Mucke L. Inflammation in neurodegenerative disease - a double-edged sword. Neuron 35 (2002) 419-432
58. Wyss-Coray T., Yan F., Lin A.H., Lambris J.D., Alexander J.J., Quigg R.J., and Masliah E. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 10837-10842